At the 2012 Society of Surgical Oncology Annual Meeting, Provectus Pharmaceuticals Inc. presented non-clinical information on PV-10s immunologic mechanism, which confirms that the drug’s chemoablation of melanoma lesions results in a systemic response and initiates systemic anti-tumor immunity.
The study was undertaken in order to clarify PV-10s apparent systemic effect, which researchers noted in the drug’s clinical Phase 1 and Phase 2 trials, whereby untreated bystander lesions in some melanoma patients had regressed.
Dr. Paul Toomey, M.D., from the Moffitt Cancer Center and University of South Florida, College of Medicine in Tampa, FL, presented detailed experimental data on PV-10s immune-mediated anti-tumor response during the Annual Meeting’s melanoma poster session on March 23 and 24, 2012, which included the induction of tumor-specific interferon-gamma production by splenocytes developed after PV-10 treatment in comparison to controls.
Dr. Toomey declared:
“Our data confirms that intra-tumoral PV-10 causes both a direct anti-tumoral response of the injected tumor and a systemic tumor-specific activation of the immune system. As we continue to probe this very interesting process, we look forward to presenting further data from our ongoing research of this unique agent in both non-clinical and clinical studies.”
Craig Dees, Ph.D., CEO of Provectus added:
“We are delighted to see confirmation of the anti-tumor immunologic processes stimulated by PV-10 chemoablation and the exciting discoveries of Dr. Toomey and his colleagues that are provided in the poster presentation. We very much look forward to even more detailed data from the Moffitt team of researchers.”
Written by Petra Rattue